2.3 trillion yen in oncology revenue to be delivered by 2030 through the launch of 20 new indications across five medicines Identifying breakthrough generating technologies and strengthening of ...
Daiichi Sankyo aims to transform its antibody-drug conjugate (ADC) leadership into a top global oncology standing. In a new five-year business plan unveiled Monday, the Japanese pharma outlined a ...
Daiichi Sankyo (TSE: 4568) today revealed its next Five-Year Business Plan (FY2026 - FY2030) that outlines how the company plans to deliver more than 2.3 trillion yen in oncology revenue by 2030 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results